Viloxazine
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 435 publications
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial.
Journal: The Journal of clinical psychiatry
Published: May 28, 2026
Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.
Journal: BMJ (Clinical research ed.)
Published: November 26, 2025
Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations.
Journal: Drugs in R&D
Published: October 29, 2025
Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD.
Journal: Pharmacology & therapeutics
Published: October 06, 2025
Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system.
Journal: Medicine
Published: October 03, 2025
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials.
Journal: Expert opinion on pharmacotherapy
Published: September 23, 2025
Viloxazine occupies the 5-HT2C receptor in the macaca fascicularis brain in vivo: A [11C]CIMBI-36 positron emission tomography study.
Journal: The international journal of neuropsychopharmacology
Published: August 19, 2025
The Viloxazine Paradox: A Noradrenergic Agent's Journey From Antidepressant Obscurity to ADHD Precision Therapy.
Journal: CNS neuroscience & therapeutics
Published: August 17, 2025
Last Updated: 06/30/2026